{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:30:34Z","timestamp":1786987834930,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ecl.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:22:23Z","timestamp":1753701743000},"page":"587-607","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medical Therapies for Acromegaly"],"prefix":"10.1016","volume":"54","author":[{"given":"M\u00f4nica R.","family":"Gadelha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Aloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.007_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure'","volume":"152","author":"Nomikos","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s11102-017-0832-8","article-title":"Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly","volume":"20","author":"Fahlbusch","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","article-title":"Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system","volume":"18","author":"Nunes","year":"2015","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib11","article-title":"Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies","volume":"9","author":"Yang","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12020-021-02766-2","article-title":"GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil","volume":"74","author":"Manosso","year":"2021","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.ecl.2025.06.007_bib16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2025.06.007_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2024.101608","article-title":"Medical treatment of acromegaly - when the tumor size matters: a narrative review","volume":"78","author":"Doknic","year":"2024","journal-title":"Growth Hormone IGF Res"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib20","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2025.06.007_bib23","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1210\/jc.2008-2627","article-title":"Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2265.2005.02317.x","article-title":"Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution","volume":"63","author":"Jallad","year":"2005","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4158\/EP161439.OR","article-title":"Clinical outcomes and self-reported symptoms in patients with acromegaly: an 8-year follow-up of a lanreotide study","volume":"23","author":"Khairi","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.007_bib28","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s40618-021-01562-z","article-title":"Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience","volume":"44","author":"Sala","year":"2021","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000446542","article-title":"Long-term remission of acromegaly after octreotide withdrawal is an uncommon and frequently unsustainable event","volume":"104","author":"Casagrande","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11102-014-0608-3","article-title":"Discontinuation of somatostatin analogs while acromegaly is in long-term remission","volume":"18","author":"Hatipoglu","year":"2015","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17446651.2024.2363540","article-title":"Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use","volume":"19","author":"Fleseriu","year":"2024","journal-title":"Expet Rev Endocrinol Metabol"},{"issue":"10","key":"10.1016\/j.ecl.2025.06.007_bib32","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expet Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.007_bib37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2025.06.007_bib39","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years\u2019 single-center real-world experience","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","article-title":"Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","volume":"26","author":"Biagetti","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"10.1016\/j.ecl.2025.06.007_bib41","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.007_bib42","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ecl.2025.06.007_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1348990","article-title":"Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts\u2019 consensus statement","volume":"15","author":"Stormann","year":"2024","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ecl.2025.06.007_bib46","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","author":"Marques","year":"2023","journal-title":"Endocr Connect"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12020-023-03325-7","article-title":"De-escalation treatment with pasireotide for acromegaly: a long-term experience","volume":"80","author":"Giampietro","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","article-title":"Long-term safety and efficacy of long-acting pasireotide in acromegaly","volume":"74","author":"Akirov","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17446651.2023.2293107","article-title":"Biomarkers of response to treatment in acromegaly","volume":"19","author":"Kasuki","year":"2024","journal-title":"Expet Rev Endocrinol Metabol"},{"key":"10.1016\/j.ecl.2025.06.007_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib52","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib53","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.13313","article-title":"Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: a pathologist\u2019s perspective","volume":"35","author":"Botelho","year":"2025","journal-title":"Brain Pathol"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.007_bib55","doi-asserted-by":"crossref","first-page":"e4382","DOI":"10.1210\/clinem\/dgac584","article-title":"Routine evaluation of somatostatin receptor type 2 in patients with acromegaly: do we still need more evidence?","volume":"107","author":"Gatto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.007_bib56","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly-a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib59","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS Study","volume":"12","author":"Berton","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ecl.2025.06.007_bib61","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib62","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib63","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST Study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib64","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib65","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib66","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17446651.2016.1222899","article-title":"Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly","volume":"12","author":"Grasso","year":"2017","journal-title":"Expet Rev Endocrinol Metabol"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1055\/s-0034-1389987","article-title":"Treatment outcome results from the Bulgarian Acromegaly Database: adjuvant dopamine agonist therapy is efficient in less than one fifth of non-irradiated patients","volume":"123","author":"Vandeva","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib70","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11102-016-0737-y","article-title":"The role of combination medical therapy in the treatment of acromegaly","volume":"20","author":"Lim","year":"2017","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2265.1988.tb03695.x","article-title":"Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients","volume":"29","author":"Ferrari","year":"1988","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib72","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2025.06.007_bib73","doi-asserted-by":"crossref","first-page":"E1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly","volume":"97","author":"Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.06.007_bib74","article-title":"Cabergoline use and risk of fibrosis and insufficiency of cardiac valves : meta-analysis of observational studies. Herz","author":"De Vecchis","year":"2013","journal-title":"Cabergolingabe und Risiko einer Fibrose mit Herzklappeninsuffizienz"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","article-title":"Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas","volume":"169","author":"Auriemma","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2025.06.007_bib76","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: a case-control study","author":"Bancos","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib77","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib79","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2001-0022","article-title":"Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly","volume":"23","author":"Kopchick","year":"2002","journal-title":"Endocr Rev"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2025.06.007_bib80","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"9295","key":"10.1016\/j.ecl.2025.06.007_bib81","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib83","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-08-0990","article-title":"Successful use of weekly pegvisomant administration in patients with acromegaly","volume":"161","author":"Higham","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"16","key":"10.1016\/j.ecl.2025.06.007_bib84","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib85","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/S0004-27302011000200001","article-title":"[Recommendations of neuroendocrinology Department from Brazilian society of endocrinology and metabolism for diagnosis and treatment of acromegaly in Brazil]","volume":"55","author":"Vieira Neto","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-14-0214","article-title":"Favorable long-term outcomes of bilateral adrenalectomy in Cushing\u2019s disease","volume":"171","author":"O\u00dfwald","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant","volume":"92","author":"Parkinson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib89","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11102-008-0157-8","article-title":"Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly","volume":"12","author":"Bianchi","year":"2009","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib90","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1210\/jc.2011-1769","article-title":"Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study","volume":"97","author":"Filopanti","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib91","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/2359-3997000000210","article-title":"Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response","volume":"60","author":"Kasuki","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000448844","article-title":"The effect of the exon-3-deleted growth hormone receptor on pegvisomant-treated acromegaly: a systematic review and meta-analysis","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib93","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib94","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11102-016-0715-4","article-title":"Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients","volume":"19","author":"de Oliveira Machado","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2025.06.007_bib95","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-015-0673-2","article-title":"Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort","author":"Sievers","year":"2015","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.ecl.2025.06.007_bib97","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","author":"Franck","year":"2015","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib98","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib99","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib101","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib102","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11102-022-01208-0","article-title":"Acromegaly and pregnancy: a systematic review and meta-analysis","volume":"25","author":"Bandeira","year":"2022","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib103","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"10.1016\/j.ecl.2025.06.007_bib104","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cen.13599","article-title":"Outcome of pregnancies in a large cohort of women with acromegaly","volume":"88","author":"Jallad","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-016-0740-3","article-title":"Pregnancy and acromegaly","volume":"20","author":"Muhammad","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib106","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1507\/endocrj.EJ11-0306","article-title":"Growth of an aggressive tumor during pregnancy in an acromegalic patient","volume":"59","author":"Kasuki","year":"2012","journal-title":"Endocr J"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ecl.2014.10.015","article-title":"Pituitary tumor management in pregnancy","volume":"44","author":"Araujo","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"10.1016\/j.ecl.2025.06.007_bib108","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib109","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ecl.2025.06.007_bib111","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","author":"Ferone","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.06.007_bib112","series-title":"An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of the ACROINNOVA 1 roll-over patients subgroup","author":"Diego Ferone","year":"2024"},{"key":"10.1016\/j.ecl.2025.06.007_bib113","series-title":"An open-label long-term Phase 3 trial of CAM2029 in patients with acromegaly (ACROINNOVA 2): interim analysis of the subgroup of patients \u2018new to CAM2029\u2019 with controlled or uncontrolled acromegaly on standard-of-care treatment","author":"Diego","year":"2024"},{"key":"10.1016\/j.ecl.2025.06.007_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101906","article-title":"Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine","author":"Wildemberg","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2025.06.007_bib116","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.1201","article-title":"12535 efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled pathfndr-2 study","volume":"8","author":"Biller","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.06.007_bib117","article-title":"New treatments for acromegaly in development","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"issue":"12","key":"10.1016\/j.ecl.2025.06.007_bib118","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/17512433.2021.1986004","article-title":"Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly","volume":"14","author":"Neggers","year":"2021","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.ecl.2025.06.007_bib119","unstructured":"Simona Ispas-Jouron AM, Dalit Rechavi-Robinson, Daniel Biasse, Moritz Marquardt, Bruno Gavillet, Claire Laprun, Anne Bellon, Pedro Caetano, Przemys\u0142aw Witek, Mikkel Andreassen, Philippe Chanson, Thierry Brue. Debio 4126, a new 12-week octreotide formulation, provides maintenance of disease control in patients with acromegaly switching from long-acting somatostatin analogues (SSAs) \u2013 preliminary results. 2024."},{"issue":"4","key":"10.1016\/j.ecl.2025.06.007_bib120","article-title":"A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist, in healthy subjects","volume":"99","author":"Allas","year":"2024","journal-title":"Endocr Abstr"},{"issue":"3","key":"10.1016\/j.ecl.2025.06.007_bib121","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s12020-024-03741-3","article-title":"Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide","volume":"84","author":"Johnsson","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.ecl.2025.06.007_bib122","doi-asserted-by":"crossref","first-page":"K8","DOI":"10.1093\/ejendo\/lvad171","article-title":"A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas","volume":"190","author":"Regazzo","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.06.007_bib123","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.06.007_bib124","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae033","article-title":"A potent neutralizing monoclonal antibody to human growth hormone suppresses insulin-like growth factor-1 in female rats","volume":"165","author":"Hata","year":"2024","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.06.007_bib125","article-title":"OR27-4 placebo-controlled and open-label extension study of a novel hepatic-targeted antisense cimdelirsen (IONIS-GHR-LRx) under investigation in acromegaly patients","volume":"6","author":"Bhanot","year":"2022","journal-title":"J Endocr Soc"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:33:53Z","timestamp":1761147233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889852925000738"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.007","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies for Acromegaly","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}